To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

Company

Corify Care SL

Corify Care SL_logo
15
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

CORIFY Care SL is a medical start-up focused on cardiac arrhythmias. We are developing a novel technology to improve the treatment of atrial fibrillation.

Madrid, Madrid, Spain

Send a message

  • 6

    employees

English

Corify Care SL

English

CORIFY Care SL (Corify) is a medical start-up focused on cardiac arrhythmias. We are developing a novel technology to improve the treatment of atrial fibrillation, which affects more than 30M patients worldwide. Corify vision is to become the world reference company in the prognosis and treatments of patients with cardiac arrhythmias.

Corify was founded by Andreu Climent and María Guillem, biomedical engineers, together with Felipe Atienza and Francisco Fernández-Avilés,...

See more

CORIFY Care SL (Corify) is a medical start-up focused on cardiac arrhythmias. We are developing a novel technology to improve the treatment of atrial fibrillation, which affects more than 30M patients worldwide. Corify vision is to become the world reference company in the prognosis and treatments of patients with cardiac arrhythmias.

Corify was founded by Andreu Climent and María Guillem, biomedical engineers, together with Felipe Atienza and Francisco Fernández-Avilés, world-renowned physiologists on cardiac arrhythmias. The technology originated at Hospital Universitario Gregorio Marañón (Madrid) and Universitat Politècnica de València.

The Strategic Research Agenda for cardiovascular disease (SRA-CVD) considers the improvement of the Atrial Fibrillation (AF) treatment a priority area. There are 10,7 million AF patients across Europe. By 2050, 2% of the population will be affected by AF. The effective treatment is ablation. However, more than 60% of persistent AF require several procedures, amounting to €13,5 billion in wasted healthcare costs.

Corify has developed ACORYS, a medical device, combining high-density electrodes, innovative image and biosignals processing technology and artificial intelligence. First, it helps with the diagnosis; Second, it guides surgeons during the ablation procedure.The advantage is double: a more precise diagnosis and more efficient surgery. ACORYS has been preliminarily validated with more than 150 patients in Spain and US.

Our latest news

Communities

Access2EIC – Seal of Excellence
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
1931 Members